
No results matched your search
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing...
Iterum Therapeutics (ITRM) inks agreements for the purchase and sale of 17.5M ordinary shares at $2.00/share
Iterum Therapeutics' (NASDAQ:ITRM) underwriter has agreed to increase the size of previous offering and purchase 34,782,609 ordinary shares (or pre-funded warrants) at...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Neutral | Sell | Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Doji Star Bearish | 1M | Current | |||
Completed Patterns | |||||
Three Outside Up | 1H | 2 | Mar 05, 2021 19:00 | ||
Bullish Engulfing | 1H | 3 | Mar 05, 2021 18:00 | ||
Three Inside Up | 1H | 3 | Mar 05, 2021 18:00 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
FBN Holdings | 7.10 | 7.10 | 6.85 | +0.05 | +0.71% | 26.50M | 05/03 | ||
MTN Nigeria | 160.20 | 160.20 | 160.20 | -9.80 | -5.76% | 643.20K | 05/03 | ||
Guaranty Trust Bank | 31.20 | 31.05 | 30.90 | -0.50 | -1.59% | 20.83M | 05/03 | ||
Zenith Bank | 25.30 | 25.40 | 24.95 | 0.00 | 0.00% | 46.85M | 05/03 | ||
UBA | 7.95 | 7.95 | 7.85 | 0.00 | 0.00% | 23.30M | 05/03 | ||
Access Bank | 7.90 | 7.85 | 7.70 | +0.10 | +1.28% | 10.47M | 05/03 | ||
Dangote Sugar | 16.90 | 16.90 | 16.40 | +0.40 | +2.42% | 1.98M | 05/03 | ||
Lafarge Africa | 22.20 | 22.20 | 21.80 | +2.00 | +9.90% | 1.65M | 05/03 | ||
STANBIC IBTC Bank | 44.00 | 44.00 | 44.00 | +4.00 | +10.00% | 82.37K | 05/03 | ||
Oando Plc | 2.65 | 3.00 | 2.65 | -0.25 | -8.62% | 4.05M | 05/03 |
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review